| Date | Title | Description |
| 16.04.2025 | EU approves Leqembi® (lecanemab) for treatment of early Alzheimer’s disease (Extended information) | EU approves Leqembi® (lecanemab) for treatment of early Alzheimer’s disease (Extended information)
Wed, Apr 16, 2025 01:10 CET Report this content
Stockholm, April 16, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai ha... |
| 15.04.2025 | The Future of Drug Development: A New Era of Innovation and Collaboration | In the world of pharmaceuticals, innovation is the lifeblood. The landscape is shifting, driven by collaboration and cutting-edge technology. Two recent developments illustrate this trend: the European Commission's impending decision on lec... |
| 14.04.2025 | The European Commission to make final decision on EU Marketing Authorisation for lecanemab | The European Commission to make final decision on EU Marketing Authorisation for lecanemab
Mon, Apr 14, 2025 13:00 CET Report this content
Stockholm, Sweden, April 14, 2025 – The European Commission (EC) has today disclosed information that... |
| 07.04.2025 | Exidavnemab and lecanemab data presented at the 2025 AD/PD™ congress | Exidavnemab and lecanemab data presented at the 2025 AD/PD™ congress
Mon, Apr 07, 2025 12:00 CET Report this content
Stockholm, April 7, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) presented data on exidavnemab and lecanemab at th... |
| 06.04.2025 | Pillar VC's New Fund: A Catalyst for Scientific Innovation | Pillar VC has struck gold with its latest venture, closing a $175 million Fund IV. This move elevates the firm’s total assets under management to over $500 million. It’s a bold step into the future, one that promises to bridge the gap betwe... |
| 04.04.2025 | The Tug of War in Alzheimer’s Treatment: Kisunla’s Setback and the Rise of Innovative RNA Technologies | In the ever-evolving landscape of medical science, the battle against Alzheimer’s disease is a high-stakes game. Eli Lilly & Co. recently faced a significant setback with its Alzheimer’s drug, Kisunla. The European Medicines Agency (EMA... |
| 04.04.2025 | Pillar VC: $175 Million Fund IV Closed | Pillar VC recently announced its $175 million Fund IV, bringing the firm’s total assets under management to more than $500 million. And Pillar VC is also introducing three new Venture Partners, and four new Founding Pillars, a group of CEOs... |
| 02.04.2025 | Latest Innovation in Automation and AI/ML Presented at the 11th Annual Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Top biopharmas and leading biotechs discuss new trends in AI/ML and share how th... |
| 01.04.2025 | Trump’s tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks | - |
| 01.04.2025 | The European Commission refers lecanemab decision to Appeal Committee | The European Commission refers lecanemab decision to Appeal Committee
Tue, Apr 01, 2025 12:00 CET Report this content
Stockholm, Sweden, April 1, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the... |
| 29.03.2025 | Eli Lilly Alzheimer’s Drug Kisunla Fails to Get EU Backing | (Bloomberg) -- Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal bleeding in the brain.
Lilly had sought to get the dr... |
| 27.03.2025 | Latest data on lecanemab and exidavnemab to be presented at the 2025 AD/PD™ congress | Latest data on lecanemab and exidavnemab to be presented at the 2025 AD/PD™ congress
Thu, Mar 27, 2025 08:00 CET Report this content
Stockholm, March 27, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company... |
| 25.03.2025 | BioArctic’s partner Eisai presents sales simulation for Leqembi® at its annual press conference | BioArctic’s partner Eisai presents sales simulation for Leqembi® at its annual press conference
Tue, Mar 25, 2025 07:50 CET Report this content
Stockholm, Sweden, March 25, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eis... |
| 24.03.2025 | Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square | Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprint
New building will be designed to foster collaboration and spark in... |
| 22.03.2025 | America needs a jab in its corporate backside | - |
| 21.03.2025 | NVIDIA GTC: AI Innovation Driving Change in Healthcare and Drug Discovery | - |
| 12.03.2025 | Выпускайте субстанцию: фарма ищет лучшую версию себя | - |
| 06.03.2025 | The Lecanemab Dilemma: A Setback in Alzheimer’s Treatment in Australia | In a world where time is a precious commodity, the recent decision by Australia’s Therapeutic Goods Administration (TGA) to decline the registration of lecanemab for early Alzheimer’s disease (AD) feels like a cruel twist of fate. The drug,... |
| 06.03.2025 | Funding Cuts: A Looming Crisis in Global Health | In the realm of global health, funding is the lifeblood. Without it, progress stagnates, and lives hang in the balance. Recently, the World Health Organization (WHO) sounded the alarm. The United States, a key player in global health fundin... |
| 06.03.2025 | The Sound of Silence: WHO and ITU's New Standard for Gamers' Hearing Health | In a world where gaming has become a cultural phenomenon, the sound of victory often drowns out the whispers of caution. The World Health Organization (WHO) and the International Telecommunication Union (ITU) have stepped into this arena, l... |
| 03.03.2025 | Therapeutic Goods Administration decides not to register lecanemab in Australia | Therapeutic Goods Administration decides not to register lecanemab in Australia
Mon, Mar 03, 2025 09:00 CET Report this content
Stockholm, Sweden, March 3, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced toda... |
| 28.02.2025 | The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer’s disease in the EU | The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer’s disease in the EU
Fri, Feb 28, 2025 14:00 CET Report this content
Stockholm, February 28, 2025 – BioArctic AB’s (publ) (... |
| 20.02.2025 | BioArctic's Bold Moves in Alzheimer's Treatment: A New Era of Hope | In the world of biopharmaceuticals, the race against neurodegenerative diseases is relentless. BioArctic AB, a Swedish company, is at the forefront of this battle, armed with innovative technologies and strategic partnerships. Recent develo... |
| 20.02.2025 | JPMorgan’s top biopharma picks for 2025 | - |
| 18.02.2025 | Leqembi® sales reaches €200 million – first sales milestone achieved | Leqembi® sales reaches €200 million – first sales milestone achieved
Tue, Feb 18, 2025 08:00 CET Report this content
Stockholm, Sweden, February 18, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArcti... |
| 07.02.2025 | Sales of Leqembi® totaled 13.3 billion yen in the fourth quarter 2024 | Sales of Leqembi® totaled 13.3 billion yen in the fourth quarter 2024
Fri, Feb 07, 2025 04:35 CET Report this content
Stockholm, Sweden, February 7, 2025 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their qu... |
| 31.01.2025 | Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union | TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 31.01.2025 | Update on regulatory review of lecanemab for treatment of early Alzheimer’s disease in the European Union | Update on regulatory review of lecanemab for treatment of early Alzheimer’s disease in the European Union
Fri, Jan 31, 2025 12:30 CET Report this content
Stockholm, January 31, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner... |
| 31.01.2025 | Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union | TOKYO and CAMBRIDGE, Mass., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 29.01.2025 | Atalanta Therapeutics: A New Dawn in Neurological Treatments | Atalanta Therapeutics is making waves in the biotech ocean. This Boston-based company has just secured $75 million in Series B funding, a lifeline for its ambitious plans to tackle neurological diseases. The funding round was led by EQT Lif... |
| 28.01.2025 | EQT Life Sciences leads USD 97 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington’s disease | EQT Life Sciences leads USD 97 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington’s disease
Tue, Jan 28, 2025 13:00 CET Report this content
Atalanta Therapeutics is pioneering RNA int... |
| 27.01.2025 | FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer’s Disease in the US | FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer’s Disease in the US
Mon, Jan 27, 2025 00:30 CET Report this content
Stockholm, January 27, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BI... |
| 26.01.2025 | FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease | Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment
Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression an... |
| 17.01.2025 | Innovent's Breakthrough in Pancreatic Cancer Treatment: A New Hope for Patients | In the relentless battle against pancreatic cancer, a new warrior has emerged. Innovent Biologics, a biopharmaceutical company, has received Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration (NMPA)... |
| 16.01.2025 | Ouro Medicines: $120 Million Raised For Developing Immune Reset Therapeutics | Ouro Medicines, a biotechnology company creating immune reset therapeutics for people living with chronic immune-mediated diseases, announced its launch with $120 million in funding. And the company was launched by Monograph Capital in part... |
| 15.01.2025 | Revolutionizing Alzheimer’s Treatment: The Rise of Leqembi and the Future of Pharma | In the world of pharmaceuticals, change is often slow. But every so often, a breakthrough emerges that promises to reshape the landscape. Leqembi, a drug developed to combat Alzheimer’s disease, is one such breakthrough. Recently, the U.S. ... |
| 15.01.2025 | Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says | (Bloomberg) -- Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed approval for drugs to fill unmet needs, federal watchdogs said in a report.
Biogen’s Aduhelm, Sarept... |
| 14.01.2025 | FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US | FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
Tue, Jan 14, 2025 01:00 CET Report this content
Stockholm, January 14, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B... |
| 14.01.2025 | FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease | LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option
TOKYO and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. ... |
| 13.01.2025 | FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease | TOKYO and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 11.01.2025 | Biogen proposes to buy remaining stake in Sage in $442 million deal | Biogen proposes to buy remaining stake in Sage in $442 million deal
By ReutersJanuary 10, 202511:39 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Biogen logo is seen displayed in this illustra... |
| 18.12.2024 | Eli Lilly's Alzheimer's treatment approved in China | Eli Lilly's Alzheimer's treatment approved in China
By ReutersDecember 18, 20242:24 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Eli Lilly logo is shown on one of the company's offices in San... |
| 14.12.2024 | The Long Road to Hope: Navigating Alzheimer’s Drug Trials | Alzheimer’s disease is a thief. It steals memories, moments, and identities. For families, it’s a relentless battle. Each day is a new challenge, a new heartbreak. Yet, amidst the despair, there’s a flicker of hope. Clinical trials are the ... |
| 14.12.2024 | Health | Grasping for hope: The heartbreaking journey through Alzheimer’s drug trials | Researchers took Cheryl off the drug. In September, the manufacturer scrapped its national trial after results showed the medication worked no better than the placebo. Cheryl must now wait four months before enrolling in a new trial. In the... |
| 11.12.2024 | Shanghai Pharma Gains After New ALS Treatment Wins US Orphan Drug Status | (Yicai) Dec. 11 -- Shanghai Pharmaceutical’s shares rose after the firm said US authorities have granted orphan drug designation to its experimental treatment for amyotrophic lateral sclerosis, a rare and fatal neuromuscular disorder.
The c... |
| 30.11.2024 | Leqembi's Launch: A New Dawn for Alzheimer's Treatment in South Korea | In a significant stride for Alzheimer's treatment, BioArctic AB's partner, Eisai, has launched Leqembi® (lecanemab) in South Korea. This approval, granted in May 2024, marks a pivotal moment for the nearly 900,000 dementia patients in the c... |
| 28.11.2024 | Leqembi[®] launched in South Korea | Leqembi[®] launched in South Korea
Thu, Nov 28, 2024 00:30 CET Report this content
Stockholm, Sweden, November 28, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that Leqembi® (generic name: leca... |
| 19.11.2024 | Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity | Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease activityA greater response was observed acro... |
| 18.11.2024 | Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ | OPUVIZ™ is one of the first wave aflibercept biosimilars in Europe OPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen’s partnership EC approval based on robust totality of eviden... |
| 18.11.2024 | Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ | OPUVIZ™ is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen’s partnershipEC approval based on robust totality of evidence... |
| 15.11.2024 | Lecanemab: A Beacon of Hope in Alzheimer’s Treatment | In the world of Alzheimer’s treatment, a new star is rising. Lecanemab, a monoclonal antibody developed by BioArctic and Eisai, is gaining traction. Recently, the European Medicines Agency’s Committee for Medicinal Products for Human Use (C... |
| 14.11.2024 | Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease | TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ... |
| 14.11.2024 | CHMP issues positive recommendation for approval of lecanemab in the EU | CHMP issues positive recommendation for approval of lecanemab in the EU
Thu, Nov 14, 2024 17:01 CET Report this content
Stockholm, November 14, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA’s Committee for M... |
| 11.11.2024 | Navigating FDA's Diversity Action Plan Draft Guidance: From Strategic Planning Through Study Success, Upcoming Webinar Hosted by Xtalks | www.cognivia.com
In this free webinar, learn about the critical importance of a coherent and comprehensive diversity action plan-integrated approach. Gain valuable insights from industry and academic leaders on mitigating implementation cha... |
| 09.11.2024 | The Rising Tide of Biotech: Boston's Role in Global Health Transformation | Boston's biotech industry is a lighthouse in the stormy seas of global health challenges. It shines brightly, guiding innovation and collaboration. This city, with its prestigious universities and a vibrant network of biotech firms, has bec... |
| 08.11.2024 | Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 – March 2025). Sales now expected to reach JPY 42.5 billion | Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 – March 2025). Sales now expected to reach JPY 42.5 billion
Fri, Nov 08, 2024 05:00 CET Report this content
Stockholm, Sweden, November 8, 2024 – BioArctic AB's (publ) (Nasdaq ... |
| 04.11.2024 | The Impact of Boston’s Biotech Industry on Global Health | Share
Tweet
Share
Share
Email
The biotech industry in Boston is more than just a source of jobs or a pillar of the local economy; it is a powerful force in the global fight for better health. Known for its prestigious universities, research... |
| 03.11.2024 | Lecanemab: A Beacon of Hope in Alzheimer’s Treatment | In the labyrinth of Alzheimer’s disease, a new light flickers. Lecanemab, a monoclonal antibody, has emerged as a promising treatment, showing potential to slow cognitive decline in early-stage patients. Recent data presented at the Clinica... |
| 01.11.2024 | Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US | Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
Fri, Nov 01, 2024 00:30 CET Report this content
Stockholm, Sweden November 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: ... |
| 31.10.2024 | The Rise of Leqembi: A New Dawn in Alzheimer’s Treatment | In the world of Alzheimer’s research, a beacon of hope shines brighter than ever. Leqembi, a drug developed through a partnership between BioArctic and Eisai, is making waves. The latest reports reveal that Leqembi generated JPY 10 billion ... |
| 31.10.2024 | Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile | Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
Thu, Oct 31, 2024 08:30 CET Report this content
Stockholm, Sweden October 31, 2024 – BioArctic AB’... |
| 31.10.2024 | Recurrent Energy Announces Successful Operation of 134 MW Solar Project | Autodesk, Inc., Biogen Inc., EMD Electronics and Wayfair Inc. are now purchasing renewable energy from the Texas project
HOUSTON and GUELPH, ON, Oct. 31, 2024 /PRNewswire/ -- Recurrent Energy, a subsidiary of Canadian Solar Inc. ("Cana... |
| 30.10.2024 | Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease | Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
Wed, Oct 30, 2024 08:30 CET Report this content
Stockholm, Sweden, October 30, 2024 – BioArctic AB (publ) (Na... |
| 30.10.2024 | Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference | -New testing method highlights link between protofibrils and biomarkers for neurodegeneration-
-Patient and caregiver perspectives on five-year treatment with lecanemab -
- Utilization of blood biomarkers to predict brain amyloid accumulati... |
| 30.10.2024 | Leqembi® revenue totaled JPY 10 billion in the third quarter 2024 | Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
Wed, Oct 30, 2024 11:45 CET Report this content
Stockholm, Sweden, October 30, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preli... |
| 29.10.2024 | Massachusetts: The Beacon of Sustainable Biotech Innovation | Massachusetts is a powerhouse in biotechnology. It’s a state where innovation blooms like spring flowers. The rich soil of education, research, and collaboration nurtures groundbreaking advancements. This article explores how Massachusetts ... |
| 29.10.2024 | Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer | CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as Chief Medical Officer and Head of Medical Affairs, effective October 28, 2024. Dr. Quirk will report to Priya... |
| 29.10.2024 | Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases | The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen.
Collaboration leverages Neomorph's leading molecular glue discovery platform and Biogen’s deep expertise in Alzheimer... |
| 28.10.2024 | Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 | CAMBRIDGE, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Michael McDonnell, Biogen’s Executive Vice President and Chief Financial Officer, plans to retire from the company on February 28, 2025. Upo... |
| 27.10.2024 | Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 | The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab
Felzartamab, an investigational anti-CD38 monoclonal antibody, is a ... |
| 27.10.2024 | The Role of Massachusetts in Promoting Sustainable Biotech Solutions | Share
Tweet
Share
Share
Email
Massachusetts stands at the forefront of biotechnology innovation, particularly in sustainable solutions. With a rich history in education and research, this state has nurtured an ecosystem that fosters groundb... |
| 26.10.2024 | Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 | The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab
Felzartamab, an investigational anti-CD38 monoclonal antibody, is a ... |
| 24.10.2024 | Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD | Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
Thu, Oct 24, 2024 08:00 CET Report this content
Stockholm, October 24, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented wit... |
| 22.10.2024 | Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024 | Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study of felzartamab for IgA nephropathy
Additional oral presentation to examine the impact of felzartamab on key disease-relevant biomarkers
Felzartamab, an inves... |
| 17.10.2024 | BioArctic and Eisai: Navigating the Waters of Alzheimer’s Treatment | In the world of biopharma, few stories resonate as powerfully as the quest to combat Alzheimer’s disease. BioArctic AB, a Swedish company, stands at the forefront of this battle. Their flagship product, Leqembi® (lecanemab), has emerged as ... |
| 17.10.2024 | Eisai will request reconsideration of initial decision for lecanemab in Australia | Eisai will request reconsideration of initial decision for lecanemab in Australia
Thu, Oct 17, 2024 01:30 CET Report this content
Stockholm, Sweden October 17, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced to... |
| 08.10.2024 | New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA | Findings from Part B and Part C of the DEVOTE study support the clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naïve to nusinersen Investigational regimen also shows ... |
| 07.10.2024 | Operationalizing Innovative Biomarkers to Support Evolving Therapeutic and Diagnostic Landscape for Neurodegenerative Diseases, Upcoming Webinar Hosted by Xtalks | www.labcorp.com
In this free webinar, learn about the rapidly evolving landscape of Alzheimer's disease therapy development and treatment. Attendees will gain insights into the key considerations for various platforms and strategies to inco... |
| 02.10.2024 | UAE TAKES THE LEAD IN AI AS INTERNATIONAL MARKETS FACE TALENT RACE TO MEET GLOBAL DEMAND | The Future AI Economy will take centre stage at GITEX GLOBAL 2024, the world’s largest tech and startup event, taking place from 14-18 October in Dubai
Dubai, UAE: The global surge in Artificial Intelligence (AI) investments propelled by th... |
| 16.09.2024 | Autoliv Welcomes Adriana Karaboutis: A New Era in Automotive Safety Leadership | In a strategic move that signals a commitment to innovation and leadership, Autoliv, Inc. has appointed Adriana Karaboutis to its Board of Directors. This decision, effective September 13, 2024, expands the board from eleven to twelve membe... |
| 16.09.2024 | Autoliv Appoints Adriana Karaboutis to its Board of Directors | Autoliv Appoints Adriana Karaboutis to its Board of Directors
Mon, Sep 16, 2024 08:00 CET Report this content
(Stockholm, Sweden, September 16, 2024) – Autoliv, Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in automotive safety sy... |
| 16.09.2024 | Autoliv Appoints Adriana Karaboutis to its Board of Directors | STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV) (SSE: ALIVsdb), the worldwide leader in automotive safety systems, announces that it has added a new independent member to its Board of Directors effective today.
On Septem... |
| 15.09.2024 | SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit | NEW YORK, Sept. 15, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, both dates inclusive (the "... |
| 12.09.2024 | Biogen Board Appoints Two New Independent Directors | CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (Nasdaq: BIIB) Board of Directors (the “Board”) today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir... |
| 04.09.2024 | Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA | Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational dose regimen
Higher dose nusinersen regimen... |
| 04.09.2024 | Clouds of Care Secures 5 Million Euros to Propel CNS Healthcare Innovation and appoints former CEO of Biogen, Michel Vounatsos, as chairman of the board of directors | GHENT, Belgium, Sept. 4, 2024 /PRNewswire/ -- Clouds of Care, a leading MedTech company dedicated to enabling better care for people with Central Nervous System (CNS) disorders, proudly announces the successful closure of its funding round.... |
| 03.09.2024 | Pharmaceutical Market: Trends, Segmentation, and Growth Opportunities | Share
Tweet
Share
Share
Email
In recent years, the pharmaceutical market has witnessed remarkable growth and transformation, driven by technological advancements, evolving consumer needs, and the global push for better healthcare solutions.... |
| 03.09.2024 | Parkinson’s Disease Drug Market: Trends, Growth, and Segmentation | Share
Tweet
Share
Share
Email
Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, affects millions of individuals worldwide. As the global population age... |
| 03.09.2024 | Remedy Pharmaceuticals Announces Further Analyses from Phase 3 Study Reveals CIRARA Could Significantly Improve Independent Ambulation in Large Hemispheric Infarction Patients | NEW YORK, Sept. 3, 2024 /PRNewswire/ -- Remedy Pharmaceuticals today announced promising new data from the Phase 3 CHARM clinical trial of CIRARA (IV glyburide) in Large Hemispheric Infarction (LHI), the most serious form of ischemic stroke... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 22.08.2024 | Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain | Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain
Thu, Aug 22, 2024 11:05 CET Report this content
Stockholm, Sweden August 22, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today t... |
| 14.08.2024 | Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates | Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates
Wed, Aug 14, 2024 01:00 CET Report this content
Stockholm, Sweden, August 14, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announ... |
| 05.08.2024 | Фармпроизводитель из США Biogen подал иск к Минздраву России | Суть иска американской фирмой не разглашается. Возможно, речь идет о споре из-за нарушения патентного права, связанного с препаратом «Лантесенс», пишет «Ъ».
«Спинраза» один из самых дорогих препаратов в мире, применяется для терапии всех ти... |
| 01.08.2024 | Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024 | Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024
Thu, Aug 01, 2024 12:45 CET Report this content
Stockholm, Sweden, August 1, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today ... |
| 31.07.2024 | Lecanemab: A Beacon of Hope in the Fight Against Alzheimer’s Disease | In the battle against Alzheimer’s disease, a new warrior has emerged: lecanemab, marketed as LEQEMBI. Recent findings presented at the Alzheimer’s Association International Conference (AAIC) 2024 reveal that this dual-acting antibody is not... |
| 31.07.2024 | AI Helps Scots Scientists Predict Diseases 10 Years in Advance | Scottish scientists using AI to analyse medical data have been able to predict a person’s probability of developing conditions such as heart disease, type 2 diabetes, Alzheimer’s up to 10 years before a diagnosis.
The researchers have used ... |
| 30.07.2024 | The New Frontier in Biotech: Partnerships and Innovations Shaping the Future of Medicine | In the ever-evolving landscape of biotechnology, partnerships are the lifeblood of innovation. Two recent collaborations highlight this trend: GSK's partnership with Flagship Pioneering and Autobahn Therapeutics' successful funding round. B... |
| 30.07.2024 | New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alz... | - 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
- Clinical Data and Biomarkers Show Alzheimer's Disease Does Not Stop Progressing... |
| 30.07.2024 | Is it worth spending RMB 200,000 a year to delay the onset of Alzheimer’s disease? | The loss of control can strike out of the blue, even when preceded by minor symptoms.
When Zhang Li’s mother began experiencing symptoms like dizziness and poor memory, it was initially dismissed as a mild stroke—a minor ailment. However, o... |
| 30.07.2024 | New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alz... | 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
Clinical Data and Biomarkers Show Alzheimer’s Disease Does Not Stop Progressing Aft... |
